
We offer
Innovative screening technologies
DNA encoded library screening in living cells
High Fidelity Drug Discovery – Get an early lead
Proprietary technology platforms
World-leading provider of small molecule drug discovery services based on DNA-encoded library technologies
Vipergen is finding tractable hits/leads for your pharmaceutical relevant targets, using three proprietary 2nd and 3rd generation DEL technologies. Vipergen is offering different business models, including simple Fee-For-Service.

What we do
Vipergen revolutionizes drug discovery by screening for novel molecules directly in living cells, providing the tool to target complex molecular entities, improve hit rates, and develop effective pharmaceuticals. Our approach prioritizes physiological relevance, ensuring a higher success rate and lower attrition rates in drug development. We excel in finding the right molecular keys for a variety of complex biological locks.

How we do it
Our advanced technology allows us to conduct screenings in living cells, increasing the target space and reducing turnaround time significantly. Unlike traditional methods, our process does not require a purified version of the target protein, enabling us to handle even the most challenging targets with ease and to initiate screenings more rapidly.

Who we are
Vipergen stands as a pioneer in the biotech and pharmaceutical industry, driven by a commitment to innovation and excellence. Our team of highly qualified professionals brings together extensive expertise in chemistry and biology. We are recognized for our unique ability to address complex drug discovery challenges that are beyond the reach of conventional approaches.
Do you have an inquiry?
From straightforward Fee-For-Service to comprehensive joint ventures, we provide flexible partnership structures to align with your project’s distinct needs.
-
Innovative screening technologies with Cellular Binder Trap Enrichment (cBTE) & Binder Trap Enrichment (BTE)
-
Vipergen’s approach enables the discovery of novel molecules directly in living cells, improving hit rates and drug development efficiency.
-
Vipergen owns exclusive rights to its technology platforms, including YoctoReactor®, BTE, and cBTE, all secured by strong patent positions
Cellular Binder Trap Enrichment (cBTE)
-
3rd generation screening technology
-
Screening inside a living cell (unique capability)
-
Physiologically relevant conditions
-
Lower attrition rate
-
No need for purified target protein (unique capability)
-
Broader protein target space
-
Multiplexing (unique capability)


Binder Trap Enrichment (BTE)
-
2nd generation screening technology
-
Solution based (homogenous assay)
-
No matrix binders
-
No target denaturation by immobilization
-
Low false positive rate
-
Multiplexing (unique capability)
YoctoReactor (yR)
-
2nd generation library synthesis technology
-
Chemical diversity by building blocks
-
Physicochemical properties kept in check
-
100% match between code and compound
-
Purification after each synthesis step (unique capability)
-
Low false positive rate
